Bristol-myers Squibb Company Profile

What is the competitive landscape for BRISTOL-MYERS SQUIBB, and when can generic versions of BRISTOL-MYERS SQUIBB drugs launch?

BRISTOL-MYERS SQUIBB has one approved drug.

There are five US patents protecting BRISTOL-MYERS SQUIBB drugs.

There are eighty patent family members on BRISTOL-MYERS SQUIBB drugs in thirty-one countries and nineteen supplementary protection certificates in sixteen countries.

Summary for Bristol-myers Squibb

International Patents:	80
US Patents:	5
Tradenames:	1
Ingredients:	1
NDAs:	1
Patent Litigation for Bristol-myers Squibb:	See patent lawsuits for Bristol-myers Squibb
PTAB Cases with Bristol-myers Squibb as patent owner:	See PTAB cases with Bristol-myers Squibb as patent owner

Drugs and US Patents for Bristol-myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-003	Apr 13, 2016		DISCN	Yes	No	9,421,192			Y
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	8,329,159			Y
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	8,900,566
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-002	Jul 24, 2015		DISCN	Yes	No	8,900,566
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	9,421,192			Y
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-002	Jul 24, 2015		DISCN	Yes	No	9,421,192			Y
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	8,642,025		Y	Y

International Patents for Bristol-myers Squibb Drugs

Country	Patent Number	Estimated Expiration
Israel	196813
Denmark	3042901
Japan	2010535785
Mexico	2009001426
South Korea	20100042641
Japan	2015172064
Colombia	6160327

Supplementary Protection Certificates for Bristol-myers Squibb Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049522	SPC/GB15/003	United Kingdom		PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTERED: UK EU/1/14/939/001-004 20140826
2049522	300713	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2049522	C300713	Netherlands		PRODUCT NAME: DACLATASVIR EN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/939/001-004 20150119
2049522	122015000009	Germany		PRODUCT NAME: DACLATASVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE DACLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140822
2049522	211 50001-2015	Slovakia		PRODUCT NAME: DAKLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939 - EU/1/14/939/004 20140826
2049522	2015/002	Ireland		PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTRATION NO/DATE: EU/14/939/001-004 20140826
2049522	PA2015006	Lithuania		PRODUCT NAME: DACLATASVIRUM; REGISTRATION NO/DATE: EU/1/14/939/001 - EU/1/14/939/004 20140826

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb